• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TRIM24 通过 snoRNA 招募 PHAX 和 DNA-PKcs 与 Ras 突变协同促进胶质瘤进展。

TRIM24 Cooperates with Ras Mutation to Drive Glioma Progression through snoRNA Recruitment of PHAX and DNA-PKcs.

机构信息

State Key Laboratory of Systems Medicine for Cancer, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai Cancer Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.

Pediatric Translational Medicine Institute, Department of Hematology & Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai, 200127, China.

出版信息

Adv Sci (Weinh). 2024 Aug;11(29):e2400023. doi: 10.1002/advs.202400023. Epub 2024 Jun 3.

DOI:10.1002/advs.202400023
PMID:38828688
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11304257/
Abstract

The factors driving glioma progression remain poorly understood. Here, the epigenetic regulator TRIM24 is identified as a driver of glioma progression, where TRIM24 overexpression promotes HRas anaplastic astrocytoma (AA) progression into epithelioid GBM (Ep-GBM)-like tumors. Co-transfection of TRIM24 with HRas also induces Ep-GBM-like transformation of human neural stem cells (hNSCs) with tumor protein p53 gene (TP53) knockdown. Furthermore, TRIM24 is highly expressed in clinical Ep-GBM specimens. Using single-cell RNA-sequencing (scRNA-Seq), the authors show that TRIM24 overexpression impacts both intratumoral heterogeneity and the tumor microenvironment. Mechanically, HRas activates phosphorylated adaptor for RNA export (PHAX) and upregulates U3 small nucleolar RNAs (U3 snoRNAs) to recruit Ku-dependent DNA-dependent protein kinase catalytic subunit (DNA-PKcs). Overexpressed TRIM24 is also recruited by PHAX to U3 snoRNAs, thereby facilitating DNA-PKcs phosphorylation of TRIM24 at S767/768 residues. Phosphorylated TRIM24 induces epigenome and transcription factor network reprogramming and promotes Ep-GBM-like transformation. Targeting DNA-PKcs with the small molecule inhibitor NU7441 synergizes with temozolomide to reduce Ep-GBM tumorigenicity and prolong animal survival. These findings provide new insights into the epigenetic regulation of Ep-GBM-like transformation and suggest a potential therapeutic strategy for patients with Ep-GBM.

摘要

导致神经胶质瘤进展的因素仍知之甚少。在这里,鉴定出表观遗传调节剂 TRIM24 是神经胶质瘤进展的驱动因素,其中 TRIM24 过表达促进 HRas 间变性星形细胞瘤 (AA) 进展为上皮样 GBM (Ep-GBM)-样肿瘤。TRIM24 与 HRas 的共转染也诱导了 TP53 基因敲低的人神经干细胞 (hNSC) 的 Ep-GBM 样转化。此外,TRIM24 在临床 Ep-GBM 标本中高度表达。通过单细胞 RNA 测序 (scRNA-Seq),作者表明 TRIM24 过表达既影响肿瘤内异质性又影响肿瘤微环境。在机制上,HRas 激活 RNA 输出的磷酸化衔接蛋白 (PHAX),上调 U3 小核仁 RNA (U3 snoRNAs),从而招募 Ku 依赖性 DNA 依赖性蛋白激酶催化亚基 (DNA-PKcs)。过表达的 TRIM24 也被 PHAX 招募到 U3 snoRNAs,从而促进 DNA-PKcs 在 S767/768 残基上磷酸化 TRIM24。磷酸化的 TRIM24 诱导表观基因组和转录因子网络重编程,并促进 Ep-GBM 样转化。用小分子抑制剂 NU7441 靶向 DNA-PKcs 与替莫唑胺联合使用,可降低 Ep-GBM 肿瘤发生能力并延长动物存活时间。这些发现为 Ep-GBM 样转化的表观遗传调控提供了新的见解,并为 Ep-GBM 患者提供了一种潜在的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/0bc879d8e8c4/ADVS-11-2400023-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/612a34b352b1/ADVS-11-2400023-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/6afbffea7c7c/ADVS-11-2400023-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/f48cebe393b2/ADVS-11-2400023-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/2f4a016d8d3a/ADVS-11-2400023-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/319e3dd3652f/ADVS-11-2400023-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/21b5b2e60078/ADVS-11-2400023-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/24bd4f156f32/ADVS-11-2400023-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/0bc879d8e8c4/ADVS-11-2400023-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/612a34b352b1/ADVS-11-2400023-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/6afbffea7c7c/ADVS-11-2400023-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/f48cebe393b2/ADVS-11-2400023-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/2f4a016d8d3a/ADVS-11-2400023-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/319e3dd3652f/ADVS-11-2400023-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/21b5b2e60078/ADVS-11-2400023-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/24bd4f156f32/ADVS-11-2400023-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be08/11304257/0bc879d8e8c4/ADVS-11-2400023-g006.jpg

相似文献

1
TRIM24 Cooperates with Ras Mutation to Drive Glioma Progression through snoRNA Recruitment of PHAX and DNA-PKcs.TRIM24 通过 snoRNA 招募 PHAX 和 DNA-PKcs 与 Ras 突变协同促进胶质瘤进展。
Adv Sci (Weinh). 2024 Aug;11(29):e2400023. doi: 10.1002/advs.202400023. Epub 2024 Jun 3.
2
NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/.NCK1-AS1 通过调节 miR-137/ 增加胶质瘤细胞对替莫唑胺的耐药性。
Cancer Biother Radiopharm. 2020 Mar;35(2):101-108. doi: 10.1089/cbr.2019.3054. Epub 2019 Nov 21.
3
Inhibiting DNA-PK induces glioma stem cell differentiation and sensitizes glioblastoma to radiation in mice.抑制 DNA-PK 可诱导脑胶质瘤干细胞分化,并增强小鼠胶质母细胞瘤对放疗的敏感性。
Sci Transl Med. 2021 Jun 30;13(600). doi: 10.1126/scitranslmed.abc7275.
4
PHAX and CRM1 are required sequentially to transport U3 snoRNA to nucleoli.PHAX和CRM1是将U3小核仁RNA转运至核仁所依次需要的。
Mol Cell. 2004 Dec 3;16(5):777-87. doi: 10.1016/j.molcel.2004.11.013.
5
Genome-wide small noncoding RNA profiling of pediatric high-grade gliomas reveals deregulation of several miRNAs, identifies downregulation of snoRNA cluster HBII-52 and delineates H3F3A and TP53 mutant-specific miRNAs and snoRNAs.对小儿高级别神经胶质瘤的全基因组小非编码 RNA 谱分析显示,几种 miRNA 失调,鉴定出 snoRNA 簇 HBII-52 的下调,并描绘了 H3F3A 和 TP53 突变体特异性 miRNA 和 snoRNA。
Int J Cancer. 2015 Nov 15;137(10):2343-53. doi: 10.1002/ijc.29610. Epub 2015 Jun 3.
6
Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.核脂肪酸结合蛋白7免疫反应性在浸润性胶质瘤中优先表达,且与表皮生长因子受体过表达的胶质母细胞瘤的不良预后相关。
BMC Cancer. 2006 Apr 19;6:97. doi: 10.1186/1471-2407-6-97.
7
Knockdown of Cathepsin L promotes radiosensitivity of glioma stem cells both in vivo and in vitro.组织蛋白酶L的敲低可促进胶质瘤干细胞在体内和体外的放射敏感性。
Cancer Lett. 2016 Feb 28;371(2):274-84. doi: 10.1016/j.canlet.2015.12.012. Epub 2015 Dec 17.
8
EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma.表皮生长因子受体(EGFR)通过促进 p53 与 DNA 依赖性蛋白激酶催化亚基(DNA-PKcs)结合来抑制 p53 功能:胶质母细胞瘤中 EGFR 和野生型 p53 之间的非典型调控轴。
Neuro Oncol. 2022 Oct 3;24(10):1712-1725. doi: 10.1093/neuonc/noac105.
9
Upregulation of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 Promotes Radioresistance of Glioma by Repressing Semaphorin 5A.长链非编码RNA小核仁RNA宿主基因18的上调通过抑制信号素5A促进胶质瘤的放射抗性。
Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):877-887. doi: 10.1016/j.ijrobp.2016.07.036. Epub 2016 Jul 30.
10
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.YB-1 依赖的溶瘤腺病毒能有效地抑制神经胶质瘤癌症干细胞样细胞的生长。
J Transl Med. 2013 Sep 18;11:216. doi: 10.1186/1479-5876-11-216.

引用本文的文献

1
Unlocking the Therapeutic Potential of DNA-PKcs in Cancer: Comprehensive Insights into Mechanisms and Clinical Applications.挖掘DNA依赖蛋白激酶催化亚基在癌症治疗中的潜力:对其机制和临床应用的全面洞察
Cancers (Basel). 2025 Aug 26;17(17):2787. doi: 10.3390/cancers17172787.
2
Small Nucleolar RNAs: Biological Functions and Diseases.小核仁RNA:生物学功能与疾病
MedComm (2020). 2025 Jun 27;6(7):e70257. doi: 10.1002/mco2.70257. eCollection 2025 Jul.
3
Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: A Scoping Review.

本文引用的文献

1
TTFields Prolonged the PFS of Epithelioid Glioblastoma Patient: A Case Report.肿瘤电场疗法延长上皮样胶质母细胞瘤患者的无进展生存期:一例报告
Brain Sci. 2023 Apr 7;13(4):633. doi: 10.3390/brainsci13040633.
2
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review.成人脑胶质瘤和其他原发性脑恶性肿瘤:综述。
JAMA. 2023 Feb 21;329(7):574-587. doi: 10.1001/jama.2023.0023.
3
Inhibition of the PI3K/AKT/mTOR signaling promotes an M1 macrophage switch by repressing the ATF3-CXCL8 axis in Ewing sarcoma.抑制 PI3K/AKT/mTOR 信号通路通过抑制 ATF3-CXCL8 轴促进尤文肉瘤中 M1 巨噬细胞的转换。
多形性胶质母细胞瘤中的表观遗传改变作为新型治疗靶点:一项范围综述
Int J Mol Sci. 2025 Jun 12;26(12):5634. doi: 10.3390/ijms26125634.
4
Challenges and opportunities for the diverse substrates of SPOP E3 ubiquitin ligase in cancer.SPOP E3泛素连接酶的多种底物在癌症中的挑战与机遇
Theranostics. 2025 May 8;15(13):6111-6145. doi: 10.7150/thno.113356. eCollection 2025.
5
Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.克服胶质瘤中的替莫唑胺耐药性:最新进展与机制洞察
Acta Neuropathol Commun. 2025 Jun 5;13(1):126. doi: 10.1186/s40478-025-02046-4.
6
Unveiling the multifaceted functions of TRIM proteins in glioma pathogenesis.揭示TRIM蛋白在胶质瘤发病机制中的多方面功能。
Transl Oncol. 2025 Aug;58:102419. doi: 10.1016/j.tranon.2025.102419. Epub 2025 May 26.
Cancer Lett. 2023 Feb 28;555:216042. doi: 10.1016/j.canlet.2022.216042. Epub 2022 Dec 21.
4
Selective advantage of epigenetically disrupted cancer cells via phenotypic inertia.通过表型惰性选择表观遗传失调的癌细胞的优势。
Cancer Cell. 2023 Jan 9;41(1):70-87.e14. doi: 10.1016/j.ccell.2022.10.002. Epub 2022 Nov 3.
5
Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity.胶质母细胞瘤中的癌细胞自噬、重编程的巨噬细胞和重塑的血管触发肿瘤免疫。
Cancer Cell. 2022 Oct 10;40(10):1111-1127.e9. doi: 10.1016/j.ccell.2022.08.014. Epub 2022 Sep 15.
6
Structural analysis of the basal state of the Artemis:DNA-PKcs complex.Artemis:DNA-PKcs 复合物的基础状态的结构分析。
Nucleic Acids Res. 2022 Jul 22;50(13):7697-7720. doi: 10.1093/nar/gkac564.
7
EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma.表皮生长因子受体(EGFR)通过促进 p53 与 DNA 依赖性蛋白激酶催化亚基(DNA-PKcs)结合来抑制 p53 功能:胶质母细胞瘤中 EGFR 和野生型 p53 之间的非典型调控轴。
Neuro Oncol. 2022 Oct 3;24(10):1712-1725. doi: 10.1093/neuonc/noac105.
8
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.Selumetinib 治疗携带激活丝裂原活化蛋白激酶通路遗传改变的儿童和青年肿瘤患者的 II 期研究:NCI-COG 儿科 MATCH 试验的 E 臂。
J Clin Oncol. 2022 Jul 10;40(20):2235-2245. doi: 10.1200/JCO.21.02840. Epub 2022 Apr 1.
9
DNA-PKcs: A Targetable Protumorigenic Protein Kinase.DNA-PKcs:一种可靶向的促肿瘤发生蛋白激酶。
Cancer Res. 2022 Feb 15;82(4):523-533. doi: 10.1158/0008-5472.CAN-21-1756.
10
Dabrafenib plus trametinib in patients with BRAF-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.达拉非尼联合曲美替尼治疗 BRAF 突变型低级别和高级别胶质瘤患者(ROAR):一项多中心、开放标签、单臂、2 期、篮子试验。
Lancet Oncol. 2022 Jan;23(1):53-64. doi: 10.1016/S1470-2045(21)00578-7. Epub 2021 Nov 24.